Root Financial Partners’s Aquestive Therapeutics AQST Stock Holding History

Root Financial Partners’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14	Buy	+3	New	+$13	﹤0.01%	3796

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Root Financial Partners's AQST Position: Q3 2026 in Review

Root Financial Partners opened a new position in Aquestive Therapeutics (AQST) in Q3 2026: 3 shares worth $14. The stake represents ﹤0.01% of the portfolio and ranks #3796 among its holdings.

87 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

Root Financial Partners held 3 shares of Aquestive Therapeutics worth $14 as of Q3 2026.
Aquestive Therapeutics was a new Root Financial Partners position in Q3 2026.
Aquestive Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #3796 holding.
87 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.